By Tom Zanki ( December 22, 2014, 1:18 PM EST) -- Johnson & Johnson will pay $125 million, and potentially $575 million more if certain goals are met, to help develop a drug treating blood cancers through a collaboration announced Monday with its subsidiary Janssen Biotech Inc. and clinical stage company MacroGenics Inc....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.